Lundbeck raises $1.2 million by increasing share capital
Danish CNS drug specialist Lundbeck (LUN: CO) will raise 6,753,283 Danish kroner ($1,242,714) by increasing its share capital by 329,960 kroner through the exercise of employee warrants.
The increase is affected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following prices per share of nominally 5 kroner: 32,313 shares at 97 kroner; 19,551 shares at 102 kroner and 14,128 shares at 115 kroner. The increase corresponds to approximately 0.0336 % of the company's share capital.
The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares will give rights to dividends and other rights in relation to the company as of subscription, ie, inter alia full rights to dividends for the financial year 2013.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze